AvroBio Inc

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer. Dr. Escolar brings deep expertise across rare diseases, with a focus on lysosomal and neurogenetic disorders. She has been heavily involved in guiding the development of new therapies for rare diseases, including Pompe disease. “We

AVROBIO Announces the Appointment of Diana M. Escolar, M.D.

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present virtually at the ICR Conference 2021 at 11:30 a.m. ET on Thursday, Jan. 14, 2021. A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors & Media section of the Company's website at www.avrobio.com. A

AVROBIO to Present at the ICR Conference 2021

AVROBIO, Inc. is a clinical-stage gene therapy biotechnology company focused on developing single-dose curative ex-vivo lentiviral-based gene therapies for rare diseases. AVROBIO is developing a pipeline of six gene-therapeutics covering Fabry's disease (AVR-RD-01), Gaucher Type 1 (AVR-RD-02), Cystinosis (AVR-RD-04), Hunter syndrome (AVR-RD-05), Gaucher Type 3 (AVR-RD-06), and Pompe disease (AVR-RD-03), a $4.6B combined-market.

Avrobio: 3 Promising Phase 1/2 Therapeutics, $220M In Cash, And 2021 Catalysts

AVROBIO is developing gene therapies for lysosomal disorders where lifelong enzyme replacement therapy is the SoC. Early stage data shows promise.

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares of its common stock. The aggregate gross proceeds to the company from the offering, before deducting underwriting discounts and commission and estimated offering expenses, totaled $75 million. As previously announced, the company has granted the underwriters a 30-day option to purc

AVROBIO Announces Closing of Underwritten Public Offering

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $15.00 per share. Gross proceeds from the underwritten public offering will total approximately $75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the company. In addition, the company has granted

AVROBIO Announces Pricing of Underwritten Public Offering of $75 Million of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company, today announced that it intends to offer and sell, subject to market and other conditions, $75 million of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to $11.25 million of additional shares of its common stock (15 percent) offered in the public offering. All of the shares in the proposed offering are t

AVROBIO Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced positive new data across its clinical programs in Gaucher disease type 1, Fabry disease and cystinosis, further reinforcing the potential of ex vivo lentiviral gene therapy for lysosomal disorders. Additionally, AVROBIO is further expanding its lysosomal disorder pipeline with a new program in Gaucher dis

AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the third quarter ended Sept. 30, 2020 and provided a business update. “We continue to progress our clinical programs and have now dosed 12 patients across three different lysosomal disorders. We're also excited by the strategic expansion of our pipeline with a new program for Hunter

AVROBIO Reports Third Quarter 2020 Financial Results and Provides Business Update

ACADIA Pharma

Alnylam Pharmaceuticals

Biohaven Pharmaceutical Hld

BioNTech SE

Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.

5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-01, the company's investigational gene therapy for the treatment of Fabry disease. AVR-RD-01, an ex-vivo, lentiviral gene therapy, consists of the patient's own hematopoietic stem cells, genetically modified to express alpha-

AVROBIO Receives Orphan Drug Designation from the European Commission for AVR‑RD‑01, an Investigational Gene Therapy for Fabry Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that it will host a Virtual R&D Day for analysts and investors on Nov. 17, 2020, starting at 9:00 a.m. ET. AVROBIO will share updates on its clinical programs, including initial data on the first patient dosed in its Phase 1/2 trial for Gaucher disease, new data on the first two patients dosed in the

AVROBIO to Share Clinical and Pipeline Updates at Virtual R&D Day

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Gail M. Farfel, Ph.D., to its Board of Directors. Dr. Farfel brings more than 25 years of pharmaceutical development and regulatory experience in rare diseases with both large and small pharmaceutical companies. “Gail's deep experience in rare disease, with a focus on neuroscience, and

AVROBIO Appoints Dr. Gail Farfel to its Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced an exclusive, worldwide license agreement and a collaborative research funding agreement with The University of Manchester for an investigational lentiviral gene therapy for mucopolysaccharidosis type II (MPS II), or Hunter syndrome, a rare and deadly lysosomal disorder that primarily affects young boys.

AVROBIO Expands Lentiviral Gene Therapy Pipeline with Program for Hunter Syndrome

AVROBIO's (AVRO) gene therapy candidate for Gaucher disease, AVR-RD-02, gets orphan drug designation from the European Commission.

AVROBIO's Gaucher Disease Candidate Gets Orphan Drug Status

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the European Commission (EC) has granted orphan drug designation for AVR-RD-02, the company’s investigational gene therapy for the treatment of Gaucher disease. AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme tha

AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming virtual investor conferences. Jefferies Virtual Gene Therapy/Editing Summit Date: Thursday, Oct. 1, 2020 Time: 12:30 p.m. ET Chardan Virtual 4th Annual Genetic Medicines Conference Date: Tuesday, Oct. 6, 2020 Time: 2:0

AVROBIO to Present at Two Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc.

AVROBIO to Present at Three Upcoming Investor Conferences

Arcturus Therapeutics

89bio Inc

Fulcrum Therapeutics Inc

Intercept Pharma

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

5 Biotech Stocks Set to Outpace Q2 Earnings Estimates

AVROBIO Reports Second Quarter 2020 Financial Results and Provides Business Update

AVROBIO to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

AVROBIO has been struggling lately, but the selling pressure may be coming to an end soon

AVROBIO Sees Hammer Chart Pattern: Time to Buy?

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the first patient has been dosed in the company’s GuardOne clinical trial, a Phase 1/2 investigational study evaluating AVR-RD-02 for Gaucher disease type 1. The company also announced that the second patient has been dosed in the ongoing investigator-sponsored Phase 1/2 clinical trial of AVR-RD-04 f

AVROBIO Announces New Patients Dosed in Gaucher Disease and Cystinosis Clinical Trials

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Kim Raineri, as chief manufacturing and technology officer. He brings deep global experience in the cell and gene therapy industry, with a distinguished track record of innovation and implementation of Good Manufacturing Practices (GMP). AVROBIO’s founding chief manufacturing and techno

AVROBIO Announces the Appointment of Kim Raineri as Chief Manufacturing and Technology Officer

AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

News for AvroBio Inc Stock (AVRO)